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a b s t r a c t 
 
Excessive activity of neutrophils has been linked to many pathological conditions, including rheumatoid arthritis, cancer and 
Alzheimer’s disease. Calpain-I is a Ca2+-dependent protease that plays a key role in the extravasation of neutrophils from the 
blood stream prior to causing damage within affected tissues. Inhibition of calpain-I with small molecule mercaptoacrylic acid 
derivatives slows the cell spreading pro-cess of live neutrophils and so these compounds represent promising drug leads. Here 
we present the 2.05 and 2.03 Å co-crystal X-ray structures of the pentaEF hand region, PEF(S), from human calpain with (Z)-
3-(4-chlorophenyl)-2-mercaptoacrylic acid and (Z)-3-(5-bromoindol-3-yl)-2-mercaptoacrylic acid. In both structures, the a-
mercaptoacrylic acid derivatives bind between two a-helices in a hydrophobic pocket that is also exploited by a leucine 
residue of the endogenous regulatory calpain inhibitor calpast-atin. Hydrophobic interactions between the aromatic rings of 
both inhibitors and the aliphatic residues of the pocket are integral for tight binding. In the case of (Z)-3-(5-bromoindol-3-yl)-
2-mercaptoacrylic acid, hydrogen bonds form between the mercaptoacrylic acid substituent lying outside the pocket and the 
pro-tein and the carboxylate group is coplanar with the aromatic ring system. Multiple conformations of (Z)-3-(5-bromoindol-
3-yl)-2-mercaptoacrylic acid were found within the pocket. The increased potency of (Z)-3-(5-bromoindol-3-yl)-2-
mercaptoacrylic acid relative to (Z)-3-(4-chlorophenyl)-2-mercaptoacrylic acid may be a consequence of the indole group 
binding more deeply in the hydrophobic pocket of PEF(S) than the phenyl ring. 
 
 
 
 
 
 
1. Introduction 
 
The calpain family includes 15 known calcium activated cys-teine 
proteases (Sorimachi et al., 2011), of which calpain-I and cal-pain-II are the 
two best-studied isoforms (Campbell and Davies, 2012; Sorimachi et al., 
2011). They are heterodimeric proteins expressed in the cytosol and 
comprised of a large (80,000 Mr) and a small subunit (30,000 Mr). The large 
subunit contains the active site within the CysPc domain along with a calcium 
binding domain, PEF(L), a postulated phospholipid binding domain (C2L) 
and a N-terminal anchor helix (Sorimachi et al., 2011). The small subunits 
(CAPNS1) of calpain-I and calpain-II are identical (Ohno et al., 1986). 
CAPNS1 is composed of a glycine rich domain and a 
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second calcium binding domain, PEF(S). The large subunit varies 
significantly between the two isoforms with an overall sequence identity of 
62% (Imajoh et al., 1988). The concentration of calcium that is required for 
activation in vitro is 50 lM and 0.35 mM for cal-pain-I and calpain-II, 
respectively (Goll et al., 2003). 
Numerous functions have been postulated for calpain-I and cal-pain-II in 
the human body with links to signal transduction (Sato and Kawashima, 
2001), cell motility (Hallett and Dewitt, 2007), apoptosis (Harwood et al., 
2005; Orrenius et al., 2003) and the cell cycle (Schollmeyer, 1988; Zhang et 
al., 1997). The lack of availabil-ity of isoform specific calpain inhibitors has 
hindered elucidation of their exact physiological roles. Calpain-I and calpain-
II are both inhibited by the regulatory endogenous protein calpastatin (Wendt 
et al., 2004). Calpastatin contains four inhibitory domains and each of these 
domains is capable of inactivating one molecule of calpain (Emori et al., 
1987; Hanna et al., 2007). Each inhibitory domain is composed of three 
binding regions that bind to different regions of the heterodimeric protease 
(Hanna et al., 2008). Regions A and 
 C bind to the calcium binding domains PEF(L) and PEF(S), respec-tively, and 
region B binds to the CysPc domain (Hanna et al., 2008; Maki et al., 1987). 
 
Decreased levels of calpastatin as well as over-activation of cal-pain-I are 
linked to a wide variety of pathological conditions. These include 
Alzheimer’s disease (Saito et al., 1993), rheumatoid arthritis (Miller et al., 
2013), cancer (Storr et al., 2011) and ischemic cell death (Tontchev and 
Yamashima, 1999). Calpain I mediates the cell spreading behaviour of 
neutrophils, a necessary prelude to their extravasation through the blood 
vessel wall and migration towards pathogens or sites of tissue damage (Hallett 
and Dewitt, 2007). Hence calpain-I is a potential target for small molecule 
intervention (Miller et al., 2013). Previously, we have reported the synthesis 
of a series of cell permeable a-mercaptoacrylic acid derivatives that act as 
potent inhibitors of calpain-I and cause decreased rates of cell spreading in 
live neutrophils (Adams et al., 2012). We now report the binding mode of two 
a-mercaptoacrylic acid derivatives with the calcium binding domain of human 
PEF(S). PEF(S) is composed of nine a-helices that fold to form five EF-
hands. Four of these EF-hands bind calcium and the fifth is used to form the 
heterodimeric interface with the corrresponding EF-hand of PEF(L) of the 
large sub-unit (Hosfield et al., 1999; Strobl et al., 2000). Alone PEF(S) forms 
a dimer with two EFH5 binding to its respective partner (Blanchard et al., 
1997; Lin et al., 1997b; Todd et al., 2003). We have previously shown that 
halogenated indole mercaptoacrylates are more potent allosteric calpain 
inhibitors than their phenyl analogues (Adams et al., 2012). To understand the 
molecular basis of this observation, we now compare the co-crystal structures 
of PEF(S) with (Z)-3-(4-chlorophenyl)-2-mercaptoacrylic acid and (Z)-3-(5-
bromoindol-3-yl)-2-mercaptoacrylic acid. The indole group binds more 
deeply in the hydrophobic pocket of PEF(S) of human calpain, which 
suggests a mechanism for the generally increased potency of all indole-based 
inhibitors over their phenyl counterparts. 
 
 
 
 
2. Materials and methods 
 
(Z)-3-(4-Chlorophenyl)-2-mercaptoacrylic acid (1) and (Z)-3-(5-
bromoindol-3-yl)-2-mercaptoacrylic acid (2) were prepared as described 
previously (Adams et al., 2012). 
 
2.1. Expression, purification and crystallisation of PEF(S) 
 
The codon optimised gene encoding human PEF(S) was pur-chased from 
Epoch Biolabs (Texas, USA) in a pET21d vector. Human PEF(S) was 
produced in Escherichia coli BL21-CodonPlus(DE3)-RP (Agilent 
Technologies) and purified and crystallized using the same procedure 
previously described the for PEF(S) from Sus scrofa (Lin et al., 1997a). The 
crystals took approximately one week to grow. Prior to data collection 
ethylene glycol was added to the drop con-taining the crystals to a total 
concentration of 20% (w/v). The crys-tals were then harvested and flash 
frozen in liquid nitrogen. 
 
Soaking the inhibitors into the preformed crystals of PEF(S) was carried 
out 24 h prior to the harvesting of crystals. 16 mM Solu-tions of (Z)-3-(5-
bromoindol-3-yl)-2-mercaptoacrylic acid and (Z)-3-(4-chlorophenyl)-2-
mercaptoacrylic acid in the precipitant solution (50 mM sodium cacodylate, 
12.5% PEG6000, 20 mM cal-cium chloride and 10 mM DTT at pH 7.0) were 
prepared immedi-ately before soaking. 1 ll of the 16 mM solutions were 
added to the drops containing the crystals to a total concentration of 2 mM in 
the drop. 
 
 
2.2. Data collection and phasing 
 
The diffraction data were collected at Diamond Light Source (Oxford, 
UK, beamlines I03 and I04-1) at a temperature of 100 K. 
 
The wavelengths used for diffraction were 0.920 Å (unliganded-PEF(S)) and 
0.976 Å (PEF(S)-1, PEF(S)-2) with a Pilatus pixelated detector. The raw 
diffraction images were processed through the xia2 data-reduction system 
(Winter, 2010). The data were scaled, reduced and analysed using Scala 
(Evans, 2006) and Aimless (Evans and Murshudov, 2013) from the CCP4i 
package (Collabora-tive Computational Project number 4) (Potterton et al., 
2003). 
 
2.3. Molecular replacement and refinement 
 
The structures were solved with molecular replacement using Phaser 
(CCP4i) (McCoy, 2007). The search model was derived from the structure of 
PEF(S) (PDB:1ALV) (Lin et al., 1997b; McCoy, 2007). The solution 
obtained was adjusted with the COOT program (Crys-tallographic Object-
Oriented Toolkit) (Emsley and Cowtan, 2004) for molecular model building 
and completion, and the model was refined further with the Refmac5 
refinement program (Murshudov et al., 1997). The models for the small 
molecules 1 and 2, were created with ProDrg (Schuttelkopf and van Aalten, 
2004). 
 
 
3. Results and discussion 
 
The data collection and refinement statistics for human PEF(S) and 
PEF(S) complexed with 1 and 2 are reported in Table 1. The structure of 
porcine unliganded-PEF(S) was also determined for completeness (Table S1). 
The resolutions were 1.60 Å for PEF(S) and 2.03–2.05 Å for the two co-
crystal structures. 
 
Table 1 
 
The data statistics for the structures of unliganded-PEF(S), PEF(S)-1 and PEF(S)-2. 
 
Crystal form Unliganded-PEF(S) PEF(S)-1 PEF(S)-2 
    
Data collection    
X-ray source DLS I04-1 DLS I03 DLS I03 
Wavelength (Å) 0.9200 0.9673 0.9673 
Space group P1211 P1211 P1211 
Unit cell a (Å) 49.63 49.54 49.41 
b (Å) 79.31 80.09 79.34 
c (Å) 57.10 56.89 57.26 
Wilson B-factor (A2) 20.0 26.6 30.1 
Resolution (Å) 49.61–1.60 80.09–2.05 41.93–2.03 
 (1.64–1.60) (2.10–2.05) (2.08–2.03) 
Unique reflections 51,828 (3589) 25,589 (3670) 27,196 (1648) 
Multiplicity 4.1 (4.2) 3.4 (2.6) 3.5 (2.7) 
Completeness (%) 89.0 (83.8) 91.8 (70.0) 95.0 (78.4) 
Mean I/rI 12.7 (2.3) 10.8 (2.3) 17.9 (2.4) 
CC
1/2 0.997 (0.769) 0.977 (0.650) 0.994 (0.497) 
R
merge 
(%) 
5.9 (60.6) 8.3 (103.9) 5.1 (111.5) 
Refinement    
Resolution (Å) 49.61–1.60 80.09–2.05 41.93–2.03 
No. reflections 49,154 24,048 25,811 
Rwork (%) 16.6 23.1 19.7 
Rfree (%) 20.1 27.9 25.1 
No. of non H atoms    
Protein 2952 2816 2806 
Ligand/ion 8 34 56 
Water 387 141 150 
Average B-factor (A2)    
Protein 24.7 39.5 44.4 
Ions 22.0 35.4 40.6 
Ligand  78.2 79.5 
Water 34.8 41.4 46.6 
r.m.s.deviations    
Bond length (Å) 0.019 0.016 0.019 
Bond angles (L) 1.858 1.742 2.007 
Ramachandran plot    
Favoured (%) 98.9 99.1 98.5 
Allowed (%) 100 100 100 
Number of Outliers 0 0 0 
PDB code 4PJH 4PHK 4PHM 
    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. (A) Cartoon representation of the calcium bound homodimer of human PEF(S); chain A is cyan and chain B is green, calcium ions are represented as grey spheres, the N-terminus of each 
monomer is labelled. (B) The structures of 1 ((Z)-3-(5-bromoindol-3-yl)-2-mercaptoacrylic acid) and 2 ((Z)-3-(4-chlorophenyl)-2-mercaptoacrylic acid). 
 
(C) Compound 1 (stick model) bound to chain A of PEF(S), with the a-helices labelled from the N-terminus. (D) Compound 2 (stick model) bound to chain B of PEF(S), (PDB: 4PHJ, 4PHK and 
4PHM), with the a-helices labelled from the N-terminus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. A comparison of the surface at the a-mercaptoacrylic acid binding site of unliganded-PEF(S) (A), PEF(S)-1 (B) and PEF(S)-2 (C). Q175 in red (r.m.s.d. > 2), L124, V127 and V128 in orange 
(r.m.s.d > 1), H131, W168, I173 and F226 in green (r.m.s.d < 1). F139 is highlighted in orange and green in images B and C. There were two conformations of K172 (yellow) observed in A, one of 
which partially occupies the binding pocket (r.m.s.d value cannot be calculated). 
 
3.1. Unliganded structure of PEF(S) 
 
Previous structures of isolated PEF(S) have been derived from Sus scrofa 
(wild boar), while the structures discussed in this work 
 
are for human PEF(S). There is a difference of five amino acids between the 
human and porcine forms of PEF(S), namely K173R, V183T, G190C, S211N 
and G221S. These amino acids have little effect on the overall structure of 
PEF(S) as the refined structure 
 Table 2 
 
The r.m.s.d. values for the side chains in the hydrophobic pocket of PEF(S) on binding of 1 and 
2 to both chains in the homodimer (N/A = more than one conformation of the side chain in the 
unliganded-PEF(S)). Comparison between unliganded-PEF(S), PEF(S)-1 and PEF(S)-2 carried 
out using Superpose in the CCP4 package (Bailey, 1994). 
 
Residue Unliganded-PEF(S)/PEF(S)-1 Unliganded-PEF(S)/PEF(S)-2 
 r.m.s.d.  r.m.s.d.   
       
 Chain A (Å) Chain B (Å) Chain A (Å) Chain B (Å) 
      
L124 1.82 1.81 1.82 1.82  
V127 1.28 1.50 1.42 1.40  
V128 1.06 N/A 0.76 N/A 
H131 0.32 0.53 0.31 0.24  
F139 1.82 1.78 0.13 0.12  
W168 0.64 0.43 0.63 0.22  
I171 0.34 0.32 0.28 0.24  
Q175 2.32 2.61 2.59 2.45  
F226 0.27 0.26 0.18 0.18  
       
 
 
of human PEF(S) showed a homodimer in the asymmetric unit that was 
closely related that of porcine PEF(S) (Lin et al., 1997b; Todd et al., 2003). 
EF hand 5 (EFH5) bound to its respective partner in the second monomer 
with a hydrophobic patch containing I254, V256, I258 and L262 interacting 
with their counterparts at the dimer interface. The other four EF-hands all 
bind calcium ions in agreement with the structure of the porcine homologue 
(Fig. 1) (Lin et al., 1997b; Todd et al., 2003). 
 
3.2. PEF(S) with inhibitors bound 
 
The two inhibitors (Z)-3-(4-chlorophenyl)-2-mercaptoacrylic acid (1) and 
(Z)-3-(5-bromoindol-3-yl)-2-mercaptoacrylic acid (2) both bind between the 
second and fourth a-helix of PEF(S) (Fig. 1). This pocket is also known to 
accommodate a leucine resi-due from the calpastatin binding region C and 
another a-merca-ptoacrylic acid PD150606 (Hanna et al., 2008; Lin et al., 
1997b; Todd et al., 2003). To accommodate both ligands the side chain of 
Q175 that normally occupies this pocket is driven away to form a cavity for 
the ligand (Fig. 2). R.m.s.d. calculations of the side chains within the 
hydrophobic pocket using Superpose (Bailey, 1994) indicated that Q175 of 
protein chain A showed the most sig-nificant movement within the protein 
upon binding an inhibitor; the values for r.m.s.d. were 2.32 and 2.62 Å for 1 
and 2, respectively (Table 2.). These values also indicate that L124 and V127 
signifi-cantly alter their conformation upon ligand binding (Table 2.). L124 
rotates and V127 shifts to accommodate the ligand. The refined structures 
indicate that the phenyl ring of F139 undergoes a translational shift on 
compound 1 binding but this shift is not observed in the complex of PEF(S) 
with 2 (Table 2). 
 
 
The movement of these residues can be seen more clearly with a surface 
diagram of the protein (Fig. 2) as there is no hydrophobic pocket observed in 
the surface representation of unliganded-PEF(S), due to the pocket being 
filled by Q175, L124 and V127 (Fig. 2). In the presence of the inhibitors the 
residues within the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. A comparison of the inhibitor 1 (light grey) in stick form bound to chain A (A) and chain B (B) and the inhibitor 2 (dark grey) in stick form bound to chain A (C) and chain B (D) of the 
homodimer represented in cartoon format with the residues within 4 Å of the inhibitor highlighted in stick form. Inset: notable hydrogen bond between Ne2 of Q175 and the carboxylate group of 
compound 2 (distance shown in Å). The density maps are contoured to 1r. (PDB: 4PHK and 4PHM). 
  
 
pocket move to accommodate the aromatic rings of both 1 and 2 (Fig. 2). The 
volume of the pocket is dependent on the size of the aromatic ring and the 
pocket is slightly larger when 2 is bound (Fig. 2). In chain A of PEF(S)-2 two 
separate conformations of the ligand are visible within the pocket suggesting 
that the pocket might be able to accommodate ligands larger than indoles 
(Fig. 2). 
 
The 4-chlorophenyl ring of 1 sits inside the hydrophobic pocket with the 
hydrophilic a-mercaptoacrylic acid substituent adopting a conformation 
perpendicular to the aromatic ring in chains A and B of the homodimer (Fig. 
3). The majority of interactions are within the hydrophobic pocket itself. The 
CCP4i program Contact (Bailey, 1994) indicated that van der Waals (vdW) 
contacts are pre-dicted within 4 Å between the 4-chlorophenyl group and the 
alkyl chains of K173 and Q175 as well as H131, W168, L127, I171 and F226. 
No hydrogen bonds or other polar contacts were observed between the 
mercaptoacrylic acid substituent and the protein. 
 
Compound 2 adopts two separate conformations in each of the monomers 
of PEF(S) in the asymmetric unit. In chain A, the elec-tron density map 
indicated that the a-mercaptoacrylic acid lies perpendicular to the aromatic 
ring in a conformation similar to that found for 1. In chain B on the other 
hand 2 the hydrophilic group is coplanar with the aromatic ring (Fig. 3). For 
chain A, 2 adopts two conformations in the hydrophobic pocket, with the 
indole ring flipped 180L relative to the other. Hence the NH group of the 
indole ring and the thiol of the mercaptoacrylic acid substi-tuent interact with 
different residues inside the pocket. There are over 50 vdW interactions 
between the residues within the hydro-phobic pocket and the two 
conformations of 2 in chain A. Fewer interactions were observed when the 
inhibitor lies in the fully pla-nar conformation within the pocket seen in chain 
B, despite the hydrogen bond that forms between the carboxylic acid and Ne2 
of Q175, at 3.0 Å. 
 
 
The size of the aromatic ring system is an important factor for determining 
the affinity of PEF(S) for the mercaptoacrylic acid inhibitors. The binding 
pocket is flexible and able to enlarge to accommodate the larger indole ring of 
2 in addition to the larger halogen atom relative to 1. The combination of the 
ring system, halogen type and the flexible nature of the pocket may explain 
the higher affinity of 2 over 1 towards calpain-I. With increased hydrophobic 
contact with the protein, 2 will bind more tightly within the pocket. The two 
different conformations of 2 found in the structure of PEF(S) with the ligand 
bound indicate that specific bonding interactions with the NH group are not 
important for tight binding so that even larger aromatic ring systems could 
perhaps be accommodated. 
 
 
Taken together, the flexibility of the binding site in accommo-dating 
different aromatic ring conformations and the lack of polar contacts with the 
surface of the protein suggest that significant scope exists to refine our 
inhibitor design. Since the mercaptoac-rylic acid unit does not seem to be 
directly involved in binding or establishing selectivity to PEF(S), it might be 
replaced with more synthetically accessible groups or used as a spacer to 
target other interactions of the protein surface. However, although both inhib-
itors bind to the calcium binding domain PEF(S) and are hence allosteric 
modulators of calpain-I, the second calcium binding domain within the 
heterodimeric structure, PEF(L), may also bind these compounds as it is very 
similar in structure and also con-tains a binding groove occupied by a helical 
domain of calpastatin in the inhibitory complex (Hanna et al., 2008). It is the 
binding of the inhibitors to this domain that may explain the discrepancy in 
inhibition constants between the two major calpain isoforms since PEF(S) is 
identical in calpains I and II (Adams et al., 2012) and the mercaptoacrylic 
acid may play a greater role in this inter-action. The inhibitors mode of action 
may disrupt the overall movement of the domains that occurs during the 
activation of the protease. 
 
4. Conclusion 
 
Since human calpain I is a potential drug target, it is preferable to study 
the interactions of inhibitors with the human form of the enzyme. Here we 
report the first crystal structure of human calpain PEF(S). For completeness 
we also redetermined the crystal struc-ture of unliganded-PEF(S) from Sus 
scrofa at 1.79 Å resolution (PDB: 4PHN) and found that it was highly similar 
to the structure of the human homologue. The excellent quality of the crystals 
obtained enabled solution of the structures to high resolution hence allowing 
observation of multiple conformations of the inhib-itors in the co-crystals. 
 
 
The 2.03 and 2.05 Å structures of both (Z)-3-(5-bromoindol-3-yl)-2-
mercaptoacrylic acid and (Z)-3-(4-chlorophenyl)-2-merca-ptoacrylic acid 
bound to the allosteric calcium binding domain PEF(S) revealed that the 
binding pocket is flexible enabling a mul-titude of van der Waals interactions 
to tightly bind the a-merca-ptoacrylic acids. To form hydrogen bonds the a-
mercaptoacrylic acid moiety needs to remain in the plane of the aromatic ring 
but it seems likely that the hydrophilic interactions are not critical for the 
affinity of these compounds to the protein since they are only observed in one 
structure. Hydrophobic interactions are key for the stability of the complexes. 
With these new structures in hand new compounds can be developed that are 
more selective and potent inhibitors of both calpain-I and calpain II and used 
for the elucidation of the physiological role of the protease. 
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